James Battiste is a Neurology physician affiliated with OU Health Stephenson Cancer Center. OpenAlex indexes 130 publications with 4,193 citations (h-index 34); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 NE 10th St
Oklahoma City, OK 731045418
Telephone
405-271-8001Provider last certified this registry record 27 May 2022.
Clinical trials
- PARP Inhibition for Gliomas (PI-4G or π4g)
Sponsor: University of Oklahoma
- OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
Sponsor: University of Oklahoma
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Caris MPI, Inc.Program year20252 payments
- SERVIER PHARMACEUTICALS LLCProgram year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
48.1%Other antiepileptics19.2%Levetiracetam58%Lacosamide42%Part D≥19 patientsAntihistamine6.2%Hydroxyzine Pamoate100%Part D≥12 patients+ 6 more classes in this area
Cancer & immunology
17.6%Isocitrate Dehydrogenase 1 Inhibitor11.6%Tibsovo100%Part D<11 patientsKinase inhibitor3.1%Koselugo100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
16.5%Serotonin-3 Receptor Antagonist11.4%Ondansetron Hcl100%Part D≥25 patientsProton pump inhibitor5.1%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2021 per NIH RePORTER. The latest:
- Analysis of Migration Associated Treatment Resistance in Glioblastoma to Identify Novel Therapeutics
University of Oklahoma Hlth Sciences Ctr
FY2021$210,318P20GM103639 - Analysis of Migration Associated Treatment Resistance in Glioblastoma to Identify Novel Therapeutics
University of Oklahoma Hlth Sciences Ctr
FY2020$213,668P20GM103639 - Analysis of Migration Associated Treatment Resistance in Glioblastoma to Identify Novel Therapeutics
University of Oklahoma Hlth Sciences Ctr
FY2019$215,606P20GM103639
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.
Journal of Clinical Oncology
2023 - A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma
Neuro-Oncology Advances
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Adam Asch, MD
OU Health Stephenson Cancer Center
Mark Doescher, MD
OU Health Stephenson Cancer Center
Debra Richardson, MD
OU Health Stephenson Cancer Center
Robert Epstein, MD
OU Health Stephenson Cancer Center
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”